

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently amended) A compound ~~comprising a bifunctional fusion glycoprotein or bifunctional glycoprotein conjugate, the compound~~ comprising a carbohydrate complement, and: a humanized two-chain fusion protein composed of a humanized V<sub>H</sub>C<sub>H1</sub>-hinge-S-human β-glucuronidase chain and of a humanized V<sub>L</sub>C<sub>L</sub> chain

~~at least one first portion which possesses enzymatic activity;~~

~~at least one second portion which binds specifically to an epitope of a tumor specific antigen wherein the carbohydrate complement comprises an exposed terminal carbohydrate mannose residue and at least one exposed terminal carbohydrate residue selected from the group consisting of galactose, mannose, N-acetylglucosamine, N-acetylactose, glucose, fucose and N-acetylneuraminic acid, and fucose~~ wherein said bifunctional fusion glycoprotein has been synthesized in CHO cells and wherein the amount of the carbohydrates given as mol monosaccharide/mol fusion protein is 1.40 of galactose, 7.04 of mannose, 4.35 of N-acetyl glucosamine, 0.6 of fucose and 0.54 of N-acetylneuraminic acid, the cells having been selected for a high level of expression of the glycoprotein, and wherein S is a polypeptide spacer.

2-8. (Canceled)

9. (Previously presented) The compound as claimed in claim 1, wherein the tumor cell marker to which the second portions binds comprises a tumor associated antigen selected from the group consisting of CEA, N-CAM, N-cadherin, PEM, GICA, TAG-72, TFβ, GM3, GD3, GM2, GD2, GT3, HMWMAA, pMell7, gpl 13 (Mucl8), p53, p97, MAGE-1, gpl05, erbB2, EGF-R, PSA, transferrin-R, P-glycoprotein and cytokeratin.

10- 15. (Canceled)

16. (Previously presented) A pharmaceutical preparation containing the compound according to claim 1 in a pharmaceutically acceptable vehicle.

17. (Previously presented) A pharmaceutical preparation containing the compound according to claim 1, and an agent capable of lowering the pH in a tumor to be treated, in a pharmaceutically acceptable vehicle.

18-21. (Canceled)